In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, top-performing sectors, and what’s next for biotech investors.

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min While talk is brewing of a ...

A New Orleans-based biotech company has developed a breakthrough non-opioid pain medication, which is backed by funding from Ochsner Ventures, the investment arm of Ochsner Health, and from Gulf South ...

While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences. Global biotech spending ...

Funding focus is a new series analysing cash flow into the European tech ecosystem. After debuting with a look at the biggest rounds so far this year, we now turn to the largest deals in the ...

Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting ...

Pharmaceutical and biotech companies have seen a shrinking share of investments across the five boroughs in the first half of 2025 as software startups suck up more of the city’s venture capital. More ...